Skip to main
IMVT

Immunovant Inc (IMVT) Stock Forecast & Price Target

Immunovant Inc (IMVT) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 25%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

Immunovant is positioned to potentially become a leader in the autoimmune disease space with their first-in-class FcRn inhibitor, IMVT-1402. The company has a significant milestone payment to HanAll for the development and manufacturing of their product candidates, and their upcoming Phase 2b data for IMVT-1402 in difficult-to-treat rheumatoid arthritis (RA) presents a blockbuster opportunity. Despite the recent failure of a competitor's FcRn inhibitor, Immunovant's trial design and patient population differentiate them and may increase the likelihood of success.

Bears say

Immunovant is facing a negative outlook due to risks associated with their key products not being approved yet and potential safety concerns surrounding their cholesterol safety signal for IMVT-1402. Additionally, the impact of COVID-19 on clinical development and the competitive market for their first product launch are also potential risks. While their financial update for 3Q showed some improvement, with a narrower loss per share and lower expenses, it is still uncertain when they will start generating revenue as it is not expected until 2027.

Immunovant Inc (IMVT) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 25% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunovant Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunovant Inc (IMVT) Forecast

Analysts have given Immunovant Inc (IMVT) a Buy based on their latest research and market trends.

According to 8 analysts, Immunovant Inc (IMVT) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunovant Inc (IMVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.